Solving the mystery of named resource management in life sciences project management for organizational effectiveness

10 Essential dashboards for every pharma R&D portfolio management PMO

Well-designed data analytics in project management is no longer a reporting convenience. It is a strategic control tower for project portfolio performance. In complex organizations, where capital allocation, resource constraints, and regulatory pressures intersect, decision velocity depends on real-time visibility. Without a structured PMO project tracking dashboard, portfolio discussions rely on fragmented spreadsheets, static presentations, and subjective updates.For PMO leaders and senior project professionals, the question is not whether to implement a dashboard, but how to design one that scales governance and enables strategic alignment. A mature PMO dashboard connects execution data to business outcomes, making portfolio trade-offs transparent and defensible. It transforms status reporting into performance management.What Is a PMO Dashboard?A PMO dashboard is a structured, visual decision-support layer that consolidates project, financial, risk, and resource data into actionable portfolio insights.In a pharma R&D context, a dashboard must:Integrate clinical, financial, and strategic dataReflect phase-gated development realitiesIncorporate Probability of Technical and Regulatory Success (PTRS)Present risk-adjusted financial metrics (e.g., rNPV)Enable scenario modelingUnlike traditional project dashboards focused on schedule and budget, an R&D PMO dashboard must support questions such as:Where should we allocate the next $100M?Which asset creates concentration risk?What is the impact of accelerating Phase II by 6 months?Are we over-indexed in early-stage assets?Are we realizing the intended benefits?Operational dashboards focus on day-to-day execution. They highlight schedule variance, cost variance, milestone adherence, issue logs, and resource utilization. These views are often used by project managers and program leads to monitor delivery discipline.Executive-level dashboards operate at different altitudes. They aggregate portfolio-level KPIs, investment distribution, strategic alignment scores, benefit realization trends, and risk exposure summaries. Their purpose is not task tracking, but investment governance and performance oversight.A robust PMO dashboard integrates data from Project Portfolio Management (PPM) systems, financial systems, timesheets, and risk registers. The outcome is a single source of truth for portfolio performance, enabling consistent conversations across leadership forums.The 10 Important pharma Dashboards Every PMO n life sciences Should HaveThe following dashboards were selected based on three criteria: executive relevance, R&D specificity, and measurability. Each supports distinct governance decisions and should be integrated into a coherent portfolio reporting framework.Portfolio Investment Allocation DashboardObjective: The Portfolio Investment Allocation Dashboard helps ensure that financial and strategic resources are distributed optimally across a pharma R&D portfolio. It enables the PMO and executives to monitor whether investments align with therapeutic priorities, risk appetite, and long-term pipeline strategy. By visualizing capital allocation across modalities, phases, and internal versus partnered assets, it highlights areas of over- or under-investment. This dashboard also supports scenario-based reallocation decisions to maximize portfolio value while managing concentration risk.Key KPIs to Monitor:Budget vs. Actual Spend by therapeutic area, development phase, and modalityAllocation Across Phases (Discovery → Phase I–III → Regulatory)Internal vs. Partnered Asset Investment RatioRisk-Adjusted Investment Distribution (e.g., rNPV-weighted allocation)Concentration Risk Index (exposure to top 3–5 assets) 2. Clinical Milestone Performance DashboardObjective: The Clinical Milestone Performance Dashboard tracks the operational execution of clinical trials to ensure that studies progress on schedule and within defined parameters. It provides visibility into enrollment, site activation, and critical path timelines, helping PMOs identify delays or bottlenecks early. By monitoring milestone adherence across the portfolio, it allows leaders to assess program predictability and take corrective actions to avoid downstream impacts on time-to-market and overall portfolio value. This dashboard also supports scenario analysis for risk mitigation and resource planning in ongoing trials.Key KPIs to Monitor:Enrollment Velocity vs. Planned Targets (patients recruited per site over time)First Patient In (FPI) / Last Patient Out (LPO) VarianceSite Activation Timelines (planned vs. actual)Critical Path Slippage (deviation from projected milestones)Trial Completion Probability or PTRS-based Milestone Status3. Resource Capacity & Utilization DashboardObjective: The Resource Capacity & Utilization Dashboard helps PMOs ensure that human and operational resources are optimally allocated across the R&D portfolio. It provides visibility into functional workloads, skill availability, and potential bottlenecks, enabling proactive adjustments before delays occur. By monitoring both internal teams and outsourced resources, the dashboard ensures projects are adequately staffed and aligned with strategic priorities. It also supports scenario planning, helping executives assess the impact of shifting resources between high-value or time-sensitive projects.Key KPIs to Monitor:FTE Demand vs. Capacity by function (clinical operations, biostatistics, regulatory, etc.)Resource Utilization Rate (percentage of available hours allocated to active projects)Skill Gap Heatmaps (identifying critical resource shortages)Outsourcing vs. Internal Resource MixOvercommitment Index (projects exceeding available capacity)4. Risk and Issue Management DashboardObjective: The Risk and Issue Management Dashboard provide a centralized view of potential and ongoing risks across the R&D portfolio, helping PMOs proactively identify, assess, and mitigate threats to project timelines, costs, and outcomes. It tracks both the probability and impact of risks, enabling teams to prioritize critical issues and take corrective actions before they affect portfolio performance. By monitoring issues in real time, the dashboard supports transparency, accountability, and strategic decision-making across projects and therapeutic areas. It also helps in evaluating the effectiveness of mitigation plans and risk response strategies.Key KPIs to Monitor:Number of Active Risks and Issues by project, phase, and therapeutic areaRisk Severity and Probability Scores (high, medium, low)Open vs. Closed Issue Count and Resolution TimeMitigation Plan Effectiveness (percentage of risks with approved and executed mitigation strategies)Risk Exposure Trend (portfolio-level view of risk concentration over time)5. Portfolio cost dashboardObjective: The Portfolio Cost Dashboard provides a consolidated view of total R&D spend across the portfolio, enabling PMOs to monitor financial performance at both asset and portfolio levels. It helps ensure that actual spending aligns with approved budgets and long-term financial plans, while highlighting cost overruns or inefficiencies early. By tracking spend across phases, therapeutic areas, and programs, the dashboard supports better financial governance and prioritization decisions. It also enables forward-looking cost forecasting, helping leadership anticipate funding needs and optimize capital allocation.Key KPIs to Monitor:Total Portfolio Spend vs. Approved BudgetCost Variance by asset, phase, and therapeutic areaEstimate at Completion (EAC) vs. Baseline BudgetCost per Phase / Cost per AssetBurn Rate Trends (monthly/quarterly spend velocity)6. Risk-Adjusted Value DashboardObjective: The Risk-Adjusted Value Dashboard enables PMOs and leadership to evaluate the true economic potential of the R&D portfolio by incorporating uncertainty into financial projections. Instead of relying on deterministic forecasts, it applies to probability factors, such as Probability of Technical and Regulatory Success (PTRS) to estimate expected value. This allows decision-makers to compare assets on a like-for-like basis, prioritize high-value programs, and identify concentration risks within the portfolioKey KPIs to Monitor:Risk-Adjusted Net Present Value (rNPV)PTRS (Probability of Technical & Regulatory Success)Expected Commercial Value Value Concentration IndexSensitivity Analysis Outputs7. Scenario Planning & What-If DashboardObjective: The Scenario Planning & What-If Dashboard enables PMOs and executives to evaluate the impact of strategic decisions before committing resources. It allows users to simulate changes, such as accelerating or delaying assets, reallocating budgets, or adjusting resource capacity, and understand how these shifts affect portfolio value, timelines, and risk exposure. By integrating financial, clinical, and resource variables, the dashboard supports data-driven trade-off discussions during governance reviews. It also helps organizations prepare for uncertainty by comparing multiple future scenarios and identifying the most resilient portfolio strategy.Key KPIs to Monitor:Portfolio Value by Scenario Impact of Acceleration/Delay on Time-to-MarketBudget Reallocation EffectsResource Rebalancing OutcomesSensitivity Analysis Results8. Regulatory Dossier Readiness DashboardObjective: The Regulatory Dossier Readiness Dashboard provides a comprehensive view of how prepared an asset is for regulatory submission. It helps PMOs and regulatory teams track the completeness, quality, and timeliness of all required modules and supporting documentation. By highlighting gaps, dependencies, and risks in submission readiness, the dashboard enables proactive issue resolution and ensures alignment with planned submission timelines. It also supports cross-functional coordination across clinical, CMC, and regulatory teams to avoid last-minute delays.Key KPIs to Monitor:Dossier Completeness Submission Readiness Status (on-track, at-risk, delayed)Document Approval Cycle TimeNumber of Open Gaps/Deficiencies prior to submissionRegulatory Milestone Adherence (planned vs. actual submission timelines)9. External Innovation & Alliance DashboardObjective: The External Innovation & Alliance Dashboard provides visibility into the performance and contribution of partnered or in-licensed assets within the R&D portfolio. It helps PMOs and leadership monitor how collaborations, licensing deals, and strategic partnerships are delivering value against expectations. By tracking milestone achievements, financial commitments, and asset progression, the dashboard ensures that external innovation aligns with portfolio priorities. It also supports risk management by identifying underperforming partnerships or potential delays in externally sourced assets.Key KPIs to Monitor:In-Licensed vs. Internal Asset Performance (progression through phases, clinical success)Deal Milestone Payments vs. ForecastPartnership Milestone Adherence (timelines for option exercises, research deliverables)Return on Collaboration Investment (financial and strategic impact)Pipeline Contribution from External Sources (percentage of portfolio value or assets)10. Resource demand and capacity planning dashboardThe Resource Demand & Capacity Planning Dashboard enables PMOs to forecast, balance, and optimize resource needs across the R&D portfolio over time. It provides forward-looking visibility into demand generated by planned and ongoing studies versus available capacity across key functions such as clinical operations, data management, biostatistics, and regulatory. By identifying future gaps or surpluses early, the dashboard supports proactive hiring, outsourcing, or reprioritization decisions. It also plays a critical role in scenario planning by showing how pipeline changes impact resource requirements and delivery timelines.Key KPIs to Monitor:Forecasted Resource Demand vs. Available CapacityCapacity Gap/SurplusResource Demand by Pipeline Scenario Hiring & Onboarding Lead Time vs. Demand Needs Planned vs. Actual Resource Fulfillment RateFrequently Asked Questions (FAQs) PMO dashboard .faq-wrapper { max-width: 850px; margin: 20px auto; font-family: 'Open Sans', sans-serif; } .faq-item { border-bottom: 1px solid #e0e0e0; padding: 10px 0; } .faq-item summary { font-family: 'Montserrat', sans-serif; font-size: 18px; font-weight: 600; cursor: pointer; list-style: none; position: relative; padding-right: 30px; } /* Remove default marker */ .faq-item summary::-webkit-details-marker { display: none; } /* Down arrow (closed state) */ .faq-item summary::after { content: "▼"; position: absolute; right: 0; top: 0; font-size: 16px; transition: transform 0.3s ease; } /* Up arrow (open state) */ .faq-item[open] summary::after { content: "▲"; } .faq-item p { margin-top: 12px; font-family: 'Open Sans', sans-serif; font-size: 17px; line-height: 1.7; color: #272727; } 1. What is a PMO dashboard in project portfolio management? A PMO dashboard is a centralized, visual decision-support system that consolidates project, financial, risk, and resource data into actionable portfolio insights. 2. Why are PMO dashboards important in pharma R&D? PMO dashboards enable real-time visibility, faster decision-making, and better capital allocation in complex, regulated R&D environments. 3. What are the key types of pharma PMO dashboards? Key dashboards include Portfolio Investment, Clinical Milestone Performance, Resource Capacity, Risk & Issue Management, Cost Tracking, Scenario Planning, and Regulatory Readiness dashboards.

Middleware solution for a multi-CTMS environment in clinical trials

Clinical trials are increasingly decentralized, running across multiple sites and geographies. To manage the growing volume of trial data and comply with evolving regulations such as ICH E6(R3), sponsors and CROs rely on technology platforms, including multiple CTMS (Clinical Trial Management Systems) for trial operations.Though these platforms bring in an ease of data collection and processing, they also create an underlying operational inefficiency within the multi CTMS environment when they are not integrated.Wondering what that is? Let's decode further in this blogWhat is a multi CTMS environment?Many sponsors and CROs rely on multiple Clinical Trial Management Systems (CTMS) to track protocols, site activities, patient enrollment, and study progress, thus creating an enviroment where multiple CTMS platforms operate together. But managing multiple CTMS platforms brings a unique set of challenges. This is where a middleware approach for multi-CTMS becomes not just useful, but essential.What are the challenges with multi-CTMS environment?For organizations running multiple trials across regions or therapeutic areas, it is common to see:Disparate systems: Different trials may be managed on separate CTMS platforms, often with differing data structures.Siloed information: Key trial metrics, enrollment, site performance, study milestones reside in isolated systems.Manual consolidation: Teams often spend hours exporting, cleaning, and reconciling data for portfolio reporting.Delayed decision-making: Without a unified view, identifying risks, site bottlenecks, or budget variances becomes reactive rather than proactive.Middleware provides a data exchange solution, providing an interchangeable interface to each CTMS environment. Each CTMS environment will connect to a single middleware solution; from there, the middleware is responsible for transforming, routing, and synchronizing all data back into each CTMS environment.This architecture reduces the complexity of integrating multiple CTMS platforms while maintaining seamless communication among multiple clinical trial partners.How can the middleware approach solve these challenges?The use of multiple CTMS, provides the capability to be flexible; however, it also creates an environment where CROs and sponsors can struggle with lack of centralized oversight, analytics and/or RBQM frameworks.Our experience with number of clients in Pharma domain states that organizations are opting for the middleware approach which provides a practical solution for managing data across their different CTMS environments. Middleware provides the ability to manage/transfer data seamlessly from one clinical application to another, creating a means for the data to continue to "transfer" consistently between CTMSs without having to "replace" existing CTMSs.From over 20 years' experience working in the clinical trial technology and RBQM space, one thing is consistent: The success of any form of oversight in the clinical trials of today is and will be based upon not just the tools put in place but on how well those tools work together.Multiple CTMS systems operations in realityWhat is a CTMS? And how does it support clinical trials?The clinical trial management system (CTMS) is responsible for executing clinical trials by overseeing activities such as monitoring study sites, tracking milestones, and recruiting subjects. A typical CTMS will typically supports the following:Study planning and set upSite selection and activationTracking monitoring visitsManaging issues and deviationsCommunicating with investigatorsReporting on the progress of the trialThe reality of clinical operations in large pharmaIn large pharmaceutical companies, we have seen that clinical operations will typically not rely on one system. They use a combination of:A legacy CTMS for ongoing studiesA cloud-based CTMS for new studiesCRO-management of CTMS platformsRegional deployments of CTMS'sWhen this type of collection of systems is concurrently operated, data within the clinical trial system landscape will become dispersed, making it extremely difficult to maintain centralized oversight without an integration layer being in place.CTMS interconnectivity and why middleware approach is a mustIntegrating CTMS implementations is particularly important when an organization wants to have a single source of truth to view all of their clinical operational data coming from several data sources. The challenges our clients faced without CTMS implementation interconnectivity are -Duplicate studies within multiple systemsSite identifiers used inconsistentlyData reconciliation‐largely manualDelays in reporting on the operational side of the studyLimited visibility across studiesIntegrating these key pieces of clinical operational data will allow sites to have seamless information about site status, monitoring visits, and issue logs, as well as allowing operational/clinical teams to share information more easily and accurately. However, as the number of CTMS applications in an organization grow, it becomes much more difficult to maintain a direct application-to-application integration due to the complexity, difficulty of maintaining, and the validation process that must take place. This is where middleware becomes a viable, scalable solution for CTMS interconnectivity. A middleware layer acts as a central hub for integration. Each CTMS can communicate and exchange data using a standardized API or data transformation definition across the enterprise.Interoperability of CTMSWith the continual adoption of new technologies by organizations, interoperability of the different systems has become a major strategic requirement.For a modern CTMS platform to perform optimally as clinical trials become more complex at all stages, it must be able to share information with various external applications. Examples of these are analytics platforms, safety systems, and regulatory databases or repositories.Middleware does this by providing:Standardized integration formats or interfacesNormalization of data across different systemsCentralized Authentication Security Control (CAS)APIs (Application Programming Interface), with versions that are controlledYour CTMS vendor does not want to do all of these things on their own. By using middleware to allow each of the vendors to do only what they do best, sponsors can evolve/migrate their technology stack without negatively impacting their existing workflows.In terms of the Clinical Technology Ecosystem, middleware will become the unifying layer or “connective tissue.”Best practices to follow while taking the middleware approachWhen implementing middleware, it is crucial to create a single integration backbone that connects all CTMS applications rather than connecting each application point to point. There are numerous factors to take into account when implementing middleware, but below are some of the most important, identified as best practices.1. Establish a standardized data model earlyEstablish early standardization of study identifiers, site identifiers, and status definitions across all CTMS platforms to ensure consistency and eliminate the need for complex reconciliation later.2. Use middleware as your integration hubAll CTMS application systems need to be connected to the middleware rather than connecting directly to each other; this will simplify CTMS integration and provide much better maintainability of connectivity.3. Build your CTMS to be API first and event driven designBy designing your CTMS to be API first and event driven, you will have the ability to update site status, monitor activity and track issues in real-time across all of your CTMS clinical trials.4. Clearly define data ownershipDecide which clinical trial system will own specific data to minimize potential conflicts between systems.5. Ensure auditability and complianceAudit logs, traceability, and error tracking must be maintained to support the regulatory oversight of CTMS clinical trial management.6. Middleware should be designed for scalabilityConfigurable mappings and reusable services should be utilized to add other studies and/or systems without needing to redesign the middleware.If you maintain strong governance of the middleware layer, then you will be able to maintain compliance, provide scalability, and provide compliance with the clinical system integration of your multi-CTMS environments.Advantages of middleware for multi-CTMS integrationWith a middleware architecture, the operational features of the integration solution will provide many benefits.Enhanced data consistency - The centralized integration will keep the study data and site data (across all systems) synchronized.Reduced complexity of integration – The middleware approach of integrating systems will avoid having to build multiple point-to-point integrations, as all systems will connect to the middleware.Scalability - Quickly adding new clinical systems can be accomplished without having to re-engineer the entire system architecture.Improved visibility - Operational and quality teams will have one source for visibility of all trials and sites across regions.Regulatory traceability - The middleware platform will maintain integration logs and data lineage to support inspection readiness.The Future of integrating multi-CTMS platformsWith the complexity of clinical trials increasing over time, organizations are likely to expand their digital ecosystems.Some key trends we predict:Decentralized trialsReal-time data monitoringAI powered operational analyticsIntegration with wearable data platformsThese innovations will result in more systems being utilized in a clinical trial management environment. Middleware's importance will be further highlighted because it is used to connect and support the functioning of all these systems, so they operate together as one platform, instead of as individual applications.i2e Consulting offers Clinical Data solutions which are a blend of domain expertise and technical knowledge. Our Industry veteran SMEs understand the domain and data management challenges to create solutions which are fit-for-purpose. Then comes our technical experts who are well versed with the latest CTMS systems, they implement the solutions following industry best practices. Frequently Asked Questions (FAQs) .faq-wrapper { max-width: 850px; margin: 20px auto; font-family: 'Open Sans', sans-serif; } .faq-item { border-bottom: 1px solid #e0e0e0; padding: 10px 0; } .faq-item summary { font-family: 'Montserrat', sans-serif; font-size: 18px; font-weight: 600; cursor: pointer; list-style: none; position: relative; padding-right: 30px; } /* Remove default marker */ .faq-item summary::-webkit-details-marker { display: none; } /* Down arrow (closed state) */ .faq-item summary::after { content: "▼"; position: absolute; right: 0; top: 0; font-size: 16px; transition: transform 0.3s ease; } /* Up arrow (open state) */ .faq-item[open] summary::after { content: "▲"; } .faq-item p { margin-top: 12px; font-family: 'Open Sans', sans-serif; font-size: 17px; line-height: 1.7; color: #272727; } 1. What is a middleware solution for multi-CTMS in clinical trials? A middleware solution is a centralized integration layer that connects multiple CTMS platforms, enabling seamless data exchange, standardization, and real-time synchronization without replacing existing systems. 2. Why is middleware important in a multi-CTMS environment? Middleware is important because it eliminates data silos, reduces manual reconciliation, and provides a unified view of clinical trial data across multiple systems, improving decision-making and efficiency. 3. What challenges does a multi-CTMS setup create in clinical trials? A multi-CTMS setup creates challenges such as fragmented data, inconsistent identifiers, manual reporting efforts, limited visibility, and delays in identifying risks or performance issues. 4. How does middleware improve clinical trial operations? Middleware improves operations by automating data flow, enabling real-time insights, standardizing data formats, and providing centralized oversight across all clinical trial systems. 5. Can middleware integrate legacy and modern CTMS platforms? Yes, middleware can integrate both legacy and modern CTMS platforms by using APIs, data transformation, and standardized interfaces, allowing organizations to scale without replacing existing systems. 6. What are the key benefits of middleware for clinical trial integration? Key benefits include improved data consistency, reduced integration complexity, scalable architecture, enhanced visibility across trials, and better regulatory compliance through auditability and traceability.

Why OnePlan is the closest Project Online alternative for modern PPM

For pharmaceutical PMOs that operate on Project Online (PO) – stage gates, resource capacity, timesheets, portfolio dashboards and more – it’s retirement timeline is a key strategic inflection point.The transition demands a modern, Microsoft-aligned platform that preserves governance discipline while enabling more integrated, data-driven decision-making. In this blog, we’ll dive into how OnePlan stands out as the closest, like-for-like best alternative for Project Online, particularly for enterprises committed to the Microsoft ecosystem.What are the key challenges organizations face as Project Online retiresThe retirement of PO exposes structural weaknesses that were often tolerated because the platform was stable and embedded. Here are a few risks to be aware of: Type of risk What the risk typically exposes for PMOs Custom workflows & PWA technical debtYears of custom workflows and configurationsLayered PWA setup built over timeComplex reporting layers connected to legacy structure Reporting fragmentation & analytics gapsPortfolio analytics depend on external toolsManual reconciliation to generate insightsSlow scenario modelling and limited near real-time visibilityChange management & governance disruption Stage gates tightly linked to portfolio processesFinancial approvals embedded in cadenceRegulatory milestones tied to system-driven governanceResource capacity planning maturity gap Capacity visibility unsolved by tools aloneInconsistent data governance for resource inputsLack of standardized portfolio processes for capacity views .card-component { display: flex; border-radius: 17.5px; border: 1px solid #CEE0EB; background: linear-gradient(126deg, #EBF7FF 28.88%, #FFF 86.32%); font-family: 'Open Sans', sans-serif; width: 80%; margin-bottom: 20px; } .card-image { width: 30%; } .card-image img { width: 100%; height: 100%; object-fit: cover; display: block; } .card-content { width: 70%; display: flex; flex-direction: column; justify-content: center; padding: 24px 30px; gap: 8px; } .card-tag { color: #008BFF; font-size: 12px; font-weight: 700; margin: 0; } .card-title { color: #232322; font-family: Montserrat; font-size: 18px; font-weight: 700; line-height: 21px; margin: 0; } .card-description { color: #272727; font-size: 10px; font-weight: 400; line-height: 20px; margin: 0; } .btn-card { display: flex; width: 124px; height: 36px; justify-content: center; align-items: center; border-radius: 83px; background: #008BFF; color: white; font-weight: 700; font-size: 12px; text-decoration: none; margin-top: 10px; } .btn-card:hover { background: #007ACC; } /* Responsive */ @media (max-width: 768px) { .card-component { flex-direction: column; } .card-image { width: 100%; } .card-content { width: 100%; padding: 20px; } } PROJECT PORTFOLIO MANAGEMENT Microsoft Project Online alternative? Find your fit with OnePlan. Join the webinar to choose the right modern PPM solution. Join webinar OnePlan alternative to Project Online: modern PPM capabilities built for the Microsoft ecosystemOnePlan is designed to connect strategy to execution across the Microsoft stack. For organizations standardized on Microsoft 365, Power Platform, and Azure DevOps, this alignment is critical. A brief look into OnePlan’s benefits and core capabilities:Portfolio visibility with centralized dashboards across initiativesResource capacity planning to balance demand and supply across functionsFinancial management to track budgets, forecasts, and actuals at portfolio levelRoadmap and scenario planning to model trade-offs before committing investmentConfigurable governance workflows aligned to stage gates and approval hierarchies Because it integrates natively with Microsoft technologies, organizations can extend reporting through Power BI, automate workflows via Power Automate, and align work management across Teams and DevOps. For life sciences enterprises managing clinical, regulatory, and commercial programs in parallel, this unified architecture reduces manual handoffs and improves data consistency.OnePlan as a Project Online alternative: why it’s the closest replacement From a functional perspective, OnePlan maps closely to the capabilities that made Project Online central to enterprise PPM. That said, let’s dive into the features of OnePlan PPM solution compared to Project Online:1. Microsoft ecosystem integration Project Online users value tight alignment with Microsoft. OnePlan, as a Project Online replacement, preserves that ecosystem logic, integrating with Microsoft 365 and related services rather than forcing a disconnected environment.2. Ease of migrationOrganizations familiar with Microsoft-centric portfolio structures can transition governance models, project hierarchies, and reporting concepts with less conceptual disruption. This reduces user resistance and training overhead.3. Portfolio and resource management depthProject Online offered strong scheduling and resource allocation. OnePlan extends this with more structured portfolio planning and scenario capabilities, supporting executive-level trade-off analysis.4. User experienceMany legacy PWA implementations evolved into complex environments. As a Project Online alternative, OnePlan offers a modern interface that consolidates views across portfolios, resources, and financials, improving adoption across business and IT stakeholders.5. Reporting and scalabilityInstead of relying on disconnected exports, OnePlan leverages the broader Microsoft data ecosystem for scalable reporting. For global organizations with hundreds or thousands of active initiatives, this architecture supports growth without redesigning the platform.In short, OnePlan benefits over Project Online for enterprises are plenty. The tool does not just replicate Project Online; it retains the operating model discipline while enabling a more integrated portfolio management approach.What are the advantages of OnePlan PPM solution compared to other Project Online alternatives?Generic work management tools often focus on team-level task collaboration. They are effective for lightweight coordination but lack enterprise-grade portfolio governance.As the best Project Online alternative for agile teams, OnePlan differentiates itself in three areas:Strategic portfolio alignment: Initiatives can be explicitly linked to strategic themes and investment priorities, enabling structured prioritizationCross-tool orchestration: Work across multiple delivery systems can be aggregated into a single portfolio view, reducing fragmentationAdvanced analytics: Configurable dashboards and data models support scenario planning and executive reporting without heavy customizationsFor organizations that have outgrown simple task tracking but do not want to lose Microsoft alignment, these OnePlan features are critical. Note: Choosing the right platform that aligns with your portfolio goals requires a structured evaluation. For more details, read our guide on Strategic PPM tool selection.Switching from Project Online to OnePlan: a low-risk migration pathOur experts advise that a low-risk migration requires disciplined execution. Here’s our step-by-step guide on how to move to OnePlan as Project Online retires: StepActions to be taken Current-state assessment: Inventory active projects, custom fields, workflows, integrations, and reports. Configuration and data audit:Identify redundant fields, obsolete templates, and technical debt. Target design definition: Align the future OnePlan configuration to strategic portfolio objectives, not simply legacy replication.Coexistence and phased rollout: Transition portfolios in waves to minimize disruption. Integration design: Rebuild or rationalize integrations with finance, HR, and development systems. Training & change management: Equip PMs, functional leaders, and executives with clear process guidance.Consulting with a PPM partner like i2e Consulting, with deep life sciences industry expertise ensures that governance, documentation, and validation are embedded into the migration plan. The i2e point of view: futureproofing your PPM strategy with OnePlanFrom our perspective, OnePlan for Project Online users is an opportunity to elevate PPM maturity. When implemented with disciplined governance and data standards, the tool capably supports portfolio operations within a Microsoft-first ecosystem. For life sciences enterprises balancing pipeline acceleration, regulatory compliance, and capital discipline, this integrated architecture is essential.At i2e, we do not stop at replacing the tool. As certified OnePlan partners, we stay through strategy definition, configuration, integration, and change adoption. Our experts design an ideal portfolio operating model that integrates your portfolio strategy, execution, finance, and resource capacity into one decision loop. Consult with us today to start your Migration from Project Online to OnePlan.Frequently Asked Questions .faq-wrapper { max-width: 850px; margin: 20px auto; font-family: 'Open Sans', sans-serif; } .faq-item { border-bottom: 1px solid #e0e0e0; padding: 10px 0; } .faq-item summary { font-family: 'Montserrat', sans-serif; font-size: 18px; font-weight: 600; cursor: pointer; list-style: none; position: relative; padding-right: 30px; } /* Remove default marker */ .faq-item summary::-webkit-details-marker { display: none; } /* Down arrow (closed state) */ .faq-item summary::after { content: "▼"; position: absolute; right: 0; top: 0; font-size: 16px; transition: transform 0.3s ease; } /* Up arrow (open state) */ .faq-item[open] summary::after { content: "▲"; } .faq-item p { margin-top: 12px; font-family: 'Open Sans', sans-serif; font-size: 17px; line-height: 1.7; color: #272727; } 1. Why is Microsoft Project Online being retired? Microsoft Project Online is being retired as part of a shift toward modern, cloud-first and AI-enabled work management tools within the Microsoft ecosystem, with support ending on September 30, 2026. 2. What is the best alternative to Microsoft Project Online? OnePlan is widely considered a leading alternative because it offers enterprise project portfolio management (PPM), resource planning, and financial management within the Microsoft 365 ecosystem. 3. How is OnePlan different from Microsoft Project Online? OnePlan provides modern PPM capabilities such as AI-driven insights, portfolio modeling, and unified work management, while Project Online is based on legacy architecture with limited innovation. 4. What is a modern PPM solution? A modern PPM solution is a cloud-based platform that connects strategy, planning, execution, and reporting, enabling better decision-making and visibility across projects. 5. How do I choose the right Project Online alternative? To choose the right Project Online alternative, evaluate Microsoft 365 integration, scalability, and advanced PPM features like portfolio planning and reporting. Also consider ease of migration, user adoption, and AI-enabled insights to ensure a smooth transition and future-ready project management.